Literature DB >> 1688385

Construction of a recombinant bovine leukemia virus vector for analysis of virus infectivity.

D Derse1, L Martarano.   

Abstract

A recombinant bovine leukemia virus (BLV) was constructed in which the X region was replaced with the bacterial neomycin resistance gene controlled by the simian virus 40 early promoter. This virus, termed BLV-SVNEO, is a self-packaging, activator-dependent retroviral vector. Introduction of the plasmid pBLV-SVNEO into mammalian cells resulted in constitutive expression of the neo gene, whereas the BLV structural genes, gag, pol, and env, were expressed only in the presence of the two regulatory proteins, Tax and Rex. The production and release of recombinant virus by cells transfected with pBLV-SVNEO were proportional to the number of G418-resistant colonies that developed after susceptible cells were exposed to the filtered culture medium. BLV-SVNEO was able to infect cell lines of human, bovine, canine, feline, and murine origin. BLV-producing cell lines were resistant to superinfection with BLV-SVNEO. This cell-virus system should facilitate molecular genetic studies of BLV and will provide a rapid, quantitative measure of BLV infectivity in a variety of cell types. These studies also demonstrate the feasibility of using activator-dependent retroviral vectors such as BLV-SVNEO to deliver foreign genes into cells and eventually animals.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1688385      PMCID: PMC249115     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

1.  Development of leukemia and lymphosarcoma induced by bovine leukemia virus in sheep: a hematopathological study.

Authors:  S Djilali; A L Parodi; D Levy; G L Cockerell
Journal:  Leukemia       Date:  1987-11       Impact factor: 11.528

2.  Selective tropism of bovine leukemia virus (BLV) for surface immunoglobulin-bearing ovine B lymphocytes.

Authors:  D Lévy; R Kettmann; P Marchand; S Djilali; A L Parodi
Journal:  Leukemia       Date:  1987-05       Impact factor: 11.528

3.  Bovine leukemia virus replicates in sheep B lymphocytes under a T cell released factor.

Authors:  S Djilali; A L Parodi; D Levy
Journal:  Eur J Cancer Clin Oncol       Date:  1987-01

4.  Molecular cloning of infectious proviral genomes of bovine leukemia virus.

Authors:  S Itohara; K Sekikawa
Journal:  Virology       Date:  1987-07       Impact factor: 3.616

5.  Identification and some biochemical properties of the major XBL gene product of bovine leukemia virus.

Authors:  N Sagata; J Tsuzuku-Kawamura; M Nagayoshi-Aida; F Shimizu; K Imagawa; Y Ikawa
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

6.  The bovine leukemia virus X region encodes a trans-activator of its long terminal repeat.

Authors:  I Katoh; Y Yoshinaka; N Sagata; Y Ikawa
Journal:  Jpn J Cancer Res       Date:  1987-02

7.  Even transcriptionally competent proviruses are silent in bovine leukemia virus-induced sheep tumor cells.

Authors:  A Van den Broeke; Y Cleuter; G Chen; D Portetelle; M Mammerickx; D Zagury; M Fouchard; L Coulombel; R Kettmann; A Burny
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

8.  trans-acting regulation of bovine leukemia virus mRNA processing.

Authors:  D Derse
Journal:  J Virol       Date:  1988-04       Impact factor: 5.103

9.  The 3' region of bovine leukemia virus genome encodes a trans-activator protein.

Authors:  C A Rosen; J G Sodroski; L Willems; R Kettmann; K Campbell; R Zaya; A Burny; W A Haseltine
Journal:  EMBO J       Date:  1986-10       Impact factor: 11.598

10.  The bovine leukemia virus p34 is a transactivator protein.

Authors:  L Willems; A Gegonne; G Chen; A Burny; R Kettmann; J Ghysdael
Journal:  EMBO J       Date:  1987-11       Impact factor: 11.598

View more
  14 in total

1.  The mouse homolog of the bovine leukemia virus receptor is closely related to the delta subunit of adaptor-related protein complex AP-3, not associated with the cell surface.

Authors:  T Suzuki; H Ikeda
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

2.  CD154 costimulated ovine primary B cells, a cell culture system that supports productive infection by bovine leukemia virus.

Authors:  A Van den Broeke; Y Cleuter; T Beskorwayne; P Kerkhofs; M Szynal; C Bagnis; A Burny; P Griebel
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

3.  The bovine leukemia virus encapsidation signal is composed of RNA secondary structures.

Authors:  L M Mansky; R M Wisniewski
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

4.  Defibrinated bovine plasma inhibits retroviral transcription by blocking p52 activation of the NFkappaB element in the long terminal repeat.

Authors:  Marianne J van den Heuvel; Karen F Copeland; Elizabeth C Cates; Barbara J Jefferson; Robert M Jacobs
Journal:  Can J Vet Res       Date:  2007-04       Impact factor: 1.310

5.  Activator-dependent and activator-independent defective recombinant retroviruses from bovine leukemia virus.

Authors:  D Milan; J F Nicolas
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

6.  In vivo leukocyte tropism of bovine leukemia virus in sheep and cattle.

Authors:  I Schwartz; A Bensaid; B Polack; B Perrin; M Berthelemy; D Levy
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

7.  Analysis of bovine leukemia virus gag membrane targeting and late domain function.

Authors:  Huating Wang; Kendra M Norris; Louis M Mansky
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

8.  Lower mutation rate of bovine leukemia virus relative to that of spleen necrosis virus.

Authors:  L M Mansky; H M Temin
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

9.  Genetically simpler bovine leukemia virus derivatives can replicate independently of Tax and Rex.

Authors:  K Boris-Lawrie; H M Temin
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

10.  In vivo infection of sheep by bovine leukemia virus mutants.

Authors:  L Willems; R Kettmann; F Dequiedt; D Portetelle; V Vonèche; I Cornil; P Kerkhofs; A Burny; M Mammerickx
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.